Denis Soulieres, The Université de Montréal, Montréal, Canada, comments on upcoming developments in the use of immunotherapies in head and neck squamous cell carcinoma. The Phase III KEYNOTE-040 (NCT02252042) and KEYNOTE-048 (NCT02358031) trials have demonstrated the potential of incorporating immunotherapies, into combination therapies, with the latter trial showing robust 5-year survival rates. However, additional research is required to further enhance outcomes in a larger number of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

свернуть